CClinicalTrials.gg
WithdrawnNCT06994624Updated Sep 2, 2026

Clinical and Biochemical Effects of a Defined Plant-Based Diet on Heart Disease

An interventional study of Nutritional intervention in Coronary Artery Disease, sponsored by Georgia State University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Georgia State University · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Death of lead PI
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A plant-based diet will be utilized in the treatment of coronary artery disease.

Read the detailed description

Study population Men and women who have been diagnosed with coronary artery disease (CAD) at Montgomery Heart \& Wellness Clinic in Houston, TX will be recruited to participate in this randomized study. Subjects will be recruited through flyers and social media advertisements. Also, subjects should currently follow a standard western diet. Exclusion criteria include the following: current tobacco use, excessive alcohol use (defined as >2 glasses of wine or alcohol equivalent per day for men or >1 glass of wine or alcohol equivalent for women), a current cancer diagnosis, an ongoing clinically defined infection, ≥ stage 3 kidney, current pregnancy or lactation, and prior hospitalization within past 6 months.

Dietary protocol Patients will consume a defined, plant-based diet (PBD) and receive standard medical care. Subjects will consume their diets for 42-days and all food will be provided, although subjects are free to consume ad libitum within their assigned dietary protocols. Supplement use will be discontinued unless clinically indicated. As previously described, participants consuming the DPBD will consume foods within a proprietary food classification system consisting of levels 0-4b.26 These include raw fruits, berries, vegetables, oats, buckwheat, seeds and avocado. Excluded for consumption are cooked foods, animal products, free oils, soda, alcohol and coffee. The Garden Kitchen™ (Houston, TX) will provide food for subjects consuming the PBD. Dietary intake will be monitored via a 24-hour dietary recall at baseline and at day 28. All subjects will be monitored with weekly telephone or office visits by a clinical team member.

Assessment of arrhythmias To assess any arrhythmias, a carnation ambulatory telemetric monitor, a non-invasive patch placed over the sternum, will monitor cardiac rhythms for 14-days prior to dietary initiation and 14 days after the 4 weeks are complete. The percent arrhythmic burden will be automatically determined by the monitor, characterized by rapid, irregular fibrillatory waves that vary in size, shape and timing.

Biochemical analysis Blood will be collected after a 12-h fast. A standard lipid panel measuring total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides will be obtained at baseline and 28 days. In addition, inflammatory biomarkers, such as hs-CRP will also be obtained. These biomarkers will be assessed by Quest Diagnostics (Secaucus, NJ) Additional blood will be collected in red-capped venous blood collection tubes intended for serum collection. Blood will allowed to sit at room temperature for 30 min, then spun down at 5,000 RPM for 10. Blood tubes will be shipped overnight to Georgia State University (Atlanta, GA) for serum analysis and cell culture experiments. Of particular interest are antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GPx1) and catalase. Additionally, inflammatory cytokine concentrations of interleukin (IL)-6, IL-1β and tumor necrosis factor (TNF)-a will be assessed with enzyme-linked immunosorbent assay (ELISA). Nitric oxide and myeloperoxidase (MPO) will also be measured in the serum, indicative of endothelial and systemic oxidative stress. Commercially available kits Superoxide Dismutase Assay Kit, Nitrate/Nitrite Colorimetric Assay Kit, Catalase Activity Assay Kit, TNF-α (human) ELISA Kit, Interleukin-6 (human) ELISA Kit, Interleukin-1β (human) ELISA Kit, Myeloperoxidase (MPO) Activity Assay Kit and Glutathione Peroxidase Assay Kit (Cayman Chemical, Ann Arbor, MI) be used to determine the concentrations of these proteins and molecules. Human cardiomyocytes and aortic endothelial cells purchased from PromoCell (Heidelberg, Germany) will be treated with isolated serum at baseline and at 4 weeks. After 24 h incubation, cells will be collected for protein analysis, gene analysis and for morphological observations.

Endothelial function Endothelial dysfunction is tightly tied with increased reactive oxygen species and systemic inflammation, and normal endothelial function is compromised in those with CAD. Thus, assessing changes in endothelial dysfunction is prudent. [10] Endothelial-dependent vasodilation will be measured using the reactive hyperemia index (RHI) at baseline and 28 days. Participants will be asked to fast overnight (10-12 h) and refrain from all medications (including aspirin), alcohol, and caffeine for at least 24 h before reporting to the study site in the morning. Upon arrival to the study site, appropriate-sized BP and two probes will be also placed on the participant's arms and index finger of both hands, respectively. The peripheral arterial tone (PAT) signal will be measured before and after hyperemia, blood flow occlusion using a non-invasive plethysmographic method (Endo-PAT 2000, Itamar Medical Ltd). Next, BP cuff will be inflated to 60 mmHg above SBP or 200mmHg, whichever is higher, for 5 min. The cuff will then be deflated to induce reactive hyperemia and PAT signal will be recorded for another 5 min. The RHI, post-to-pre-occlusion PAT signal ratio in the occluded arm, relative to the same ratio in the control arm, and corrected for baseline vascular tone, will be calculated.

Statistical analysis Based on power analysis utilizing our preliminary data, a sample size of 15 subjects per group is sufficient to demonstrate significance between groups. A P-value = 0.05 will be deemed significant. A mixed-effect analysis of variance model will be performed followed by post-hoc analysis to find differences between groups and across time.

02

Conditions studied

  • Coronary Artery Disease
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.

Browse Coronary Artery Disease studies →

Lead sponsor

Georgia State University is the lead sponsor of 52 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis with coronary artery disease (based on current EKG or prior diagnosis)
  • New patient

Exclusion criteria

Exclusion Criteria:

  • Current tobacco use

    ->2 glasses of wine for woman, >1 glass for men

  • Current cancer diagnosis
  • An ongoing clinically defined infection
  • eGFR \< 30
  • Pregnancy
  • Lactation
  • Prior hospitalization within past 6 months
  • Unstable angina
  • Heart catheterization within past 6 months
  • Cardiac perfusion study past 6 months
  • Have not been on any form of a plant-based diet previously
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Plant-based diet

    This group will consumed a plant-based diet for 6 weeks.

    Other: Nutritional intervention

Interventions

  • OtherNutritional intervention

    A plant-based diet

06

What researchers measure

Primary outcomes

  1. Improved endothelial function via reactive hyperemia index (RHI)

    Peripheral microvascular function will be measured by PAT plethysmographic device (EndoPAT, Itamar®). The device consists of a finger probe with a transducer to assess digital volume changes accompanying pulse-waves. An inflatable cuff is placed on one arm (test arm), while amplitudes are recorded from the test arm and the contralateral control arm. Reactive hyperemia index (RHI) is obtained by the following: 5 minutes of baseline amplitude signal detection, 5 minutes of arterial occlusion by suprasystolic cuff inflation, and then 6 min of post-occlusion amplitude signal detection. RHI is a unit-less measure calculated as a ratio of hyperemic to baseline flow signal. It takes into account the baseline signal and adjusts it to the changes in the contralateral arm

    Time frame: enrollment and at week 4

Secondary outcomes

  1. Arrythmia assessment

    Ambulatory telemetric monitor will be used for a 14-day period to assess abnormal incidents of QRS complex waves. These abnormal incidents will be counted and quantified. This is an external devise that uses ECG electrodes.

    Time frame: Weeks 1-2 and weeks 7-8.

07

Study locations

1 site
  • Montgomery Heart & Wellness Center
    Houston, Texas 77025, United States
08

References and documents

Publications

  • Najjar RS, Moore CE, Montgomery BD. A defined, plant-based diet utilized in an outpatient cardiovascular clinic effectively treats hypercholesterolemia and hypertension and reduces medications. Clin Cardiol. 2018 Mar;41(3):307-313. doi: 10.1002/clc.22863. Epub 2018 Mar 25. PubMed 29575002 ↗

Individual participant data

Plan to share: Yes — De-identified medical data, including endothelial function and telemetry data.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06994624
Lead sponsor
Georgia State University
Collaborators
Johnsie and Aubary Montgomery Institute of Medical Education and Research
Responsible party
Rami Najjar (Postdoctoral Fellow, Georgia State University) — Principal investigator
First posted
May 29, 2025
Start date
Apr 25, 2025
Primary completion
Apr 25, 2025
Completion
Apr 25, 2025
Last update
Sep 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion